Recent Updates
Recently added Catalysts

OMS103HP-S

Phase 3

Meniscal Tear | Small molecule | Other |Omeros Corporation|Last Updated: Oct 26, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment344
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01406561Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic MeniscectomyPHASE3 COMPLETED 344Aug 1, 2011Dec 1, 2012Oct 26, 201818 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
KOOS Symptoms Subscale
30 days

To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee symptoms as measured by the KOOS Symptoms subscale through Day 30.

Safety
90 days

To evaluate the safety of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on safety as measured by adverse events.

Secondary Endpoints
Knee Function in Sport Active patients
30 Days
Knee Pain
30 days
Quality of Life
30 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
OMS103HP-SEXPERIMENTALOMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
Vehicle Irrigation SolutionPLACEBO_COMPARATORVehicle Irrigation Solution
Interventions
NameTypeDescription
OMS103HP-SDRUGProprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
VehicleDRUG3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites18

Inclusion Criteria: 1. Voluntarily provide written informed consent in accordance with governing Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements, local regulations, and Health Insurance Portability and Accountability Act (HIPAA) Authorization (or equivalent if local...

Countries:United States
Unlock Eligibility Criteria